Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has been egranted an additional U.S. Patent, No. 12,357,590, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).